Hepatitis C Articles (HCV)
Back
	Boerhinger Ingelheim HCV Drugs Development- Protease, Polymerase       Boehringer Ingelheim starts patient recruitment in HCV drug trial Phase 3 Protease Inhibitor BI201335 - (04/29/11)   EASL: Boehringer Ingelheim's Lead Hepatitis C Compound Moves into Phase 3 - the First Within the BI HCV Portfolio - (04/04/11)   Here are key BI HCV Drug Study Results: BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days ... Nov 3, 2009 ... Background: BI 207127 is a potent and specific non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase in vitro. ... www.natap.org/2009/AASLD/AASLD_10.htm- Cached   4 week therapy with the non-nucleosidic polymerase inhibitor BI ... Apr 18, 2010 ... Conclusions: BI 207127 in combination therapy with PegIFN/RBV .... After 4 weeks treatment with 400, 600 and 800 mg BI 207127 tid, 4/6, ... www.natap.org/2010/EASL/EASL_34.htm - Cached   Strong antiviral activity and safety of IFN-sparing treatment with ...the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial Nov 3, 2010 ... Background: BI 201335 and BI 207127 are potent and specific inhibitors of the hepatitis C virus (HCV) NS3/4A protease and the NS5B ... www.natap.org/2010/AASLD/AASLD_30.htm - Cached   EASL: Positive Phase 2 results reported with Boehringer Ingelheim's investigational HCV protease inhibitor in both previously treated and untreated patient - (04/04/11)   EASL: SILEN-C1: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic genotype-1 HCV infection- (04/01/11)   EASL: SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1 patients with nonresponse to PegIFN/RBV - (04/01/11)   SVR and pharmacokinetics of the HCV protease inhibitor BI 201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV - (04/11/11)   BI 201335 pharmacokinetics and early effect on viral load in HCV ...genotype-1 patients EASL: SILEN-C1: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in ... www.natap.org/2011/EASL/EASL_80.htm - Cached           View Older Articles   Back to Top   www.natap.org